Gout
Authors: Jennifer F. Wilson
Journal: Annals of Internal Medicine (2010)

In the Clinic2 February 2010GoutChristine Laine, MD, MPH, Barbara J. Turner, MD, MSED, Sankey Williams, MD, and Jennifer F. WilsonChristine Laine, MD, MPHSearch for more papers by this author, Barbara J. Turner, MD, MSEDSearch for more papers by this author, Sankey Williams, MDSearch for more papers by this author, and Jennifer F. WilsonSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-152-3-201002020-01002 SectionsSupplemental MaterialAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Editor's Note: This issue of In the Clinic has been updated.For several thousand years, gout has been recognized as a very painful form of acute and frequently recurrent arthritis. Gout is increasing in prevalence because of the higher prevalence of obesity, a high-caloric Western diet, diuretic use, and an aging population (1). Gout currently affects more than 5 million persons in the United States alone (2). It is the most common cause of inflammatory arthritis in men, with the highest incidence in men in their forties. Gout is caused by monosodium urate (MSU) crystals formed in joints and tissues ...References1. Wallace KL, Riedel AA, Joseph-Ridge N, et al. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol. 2004;31:1582-7. [PMID:15290739] Google Scholar2. Wu EQ, Patel PA, Mody RR, et al. Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter? J Rheumatol. 2009;36:1032-40. [PMID:19369467] Google Scholar3. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987;82:421-6. [PMID:3826098] Google Scholar4. Vitart V, Rudan I, Hayward C, et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet. 2008;40:437-42. [PMID:18327257] Google Scholar5. Choi HK, Atkinson K, Karlson EW, et al. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med. 2005;165:742-8. [PMID:15824292] Google Scholar6. Choi HK, Atkinson K, Karlson EW, et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004;350:1093-103. [PMID:15014182] Google Scholar7. Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ. 2008;336:309-12. [PMID:18244959] Google Scholar8. Choi HK, Curhan G. Beer, liquor, and wine consumption and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2004;51:1023-9. [PMID:15593346] Google Scholar9. Choi HK, Atkinson K, Karlson EW, et al. Alcohol intake and risk of incident gout in men: a prospective study. Lancet. 2004;363:1277-81. [PMID:15094272] Google Scholar10. Lin JL, Tan DT, Ho HH, et al. Environmental lead exposure and urate excretion in the general population. Am J Med. 2002;113:563-8. [PMID:12459402] Google Scholar11. Suppiah R, Dissanayake A, Dalbeth N. High prevalence of gout in patients with Type 2 diabetes: male sex, renal impairment, and diuretic use are major risk factors. N Z Med J. 2008;121:43-50. [PMID:18841184] Google Scholar12. Davidson MB, Thakkar S, Hix JK, et al. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med. 2004;116:546-54. [PMID: 15063817] Google Scholar13. Giordano N, Santacroce C, Mattii G, et al. Hyperuricemia and gout in thyroid endocrine disorders. Clin Exp Rheumatol. 2001;19:661-5. [PMID:11791637] Google Scholar14. Dehghan A, Köttgen A, Yang Q, et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet. 2008;372:1953-61. [PMID:18834626] Google Scholar15. Chen SY, Chen CL, Shen ML, et al. Clinical features of familial gout and effects of probable genetic association between gout and its related disorders. Metabolism. 2001;50:1203-7. [PMID:11586494] Google Scholar16. Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008;26:2767-78. [PMID:18509186] Google Scholar17. Bosly A, Sonet A, Pinkerton CR, et al. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer. 2003;98:1048-54. [PMID:12942574] Google Scholar18. Coutinho Tde A, Turner ST, Peyser PA, et al. Associations of serum uric acid with markers of inflammation, metabolic syndrome, and subclinical coronary atherosclerosis. Am J Hypertens. 2007;20:83-9. [PMID:17198917] Google Scholar19. Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol. 2005;25:39-42. [PMID:15660333] Google Scholar20. Fröhlich M, Imhof A, Berg G, et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care. 2000;23:1835-9. [PMID:11128362] Google Scholar21. Cao JJ, Arnold AM, Manolio TA, et al. Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the Cardiovascular Health Study. Circulation. 2007;116:32-8. [PMID:17576871] Google Scholar22. Krishnan E, Baker JF, Furst DE, et al. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006;54:2688-96. [PMID:16871533] Google Scholar23. Choi HK. Diet, alcohol, and gout: how do we advise patients given recent developments? Curr Rheumatol Rep. 2005;7:220-6. [PMID:15918999] Google Scholar24. Niskanen LK, Laaksonen DE, Nyyssönen K, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med. 2004;164:1546-51. [PMID:15277287] Google Scholar25. Malik A, Schumacher HR, Dinnella JE, et al. Clinical diagnostic criteria for gout: comparison with the gold standard of synovial fluid crystal analysis. J Clin Rheumatol. 2009;15:22-4. [PMID:19125136] Google Scholar26. Mandell BF. Clinical manifestations of hyperuricemia and gout. Cleve Clin J Med. 2008;75 Suppl 5:S5-8. [PMID:18822469] Google Scholar27. Schlesinger N, Norquist JM, Watson DJ. Serum urate during acute gout. J Rheumatol. 2009;36:1287-9. [PMID:19369457] Google Scholar28. Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20:895-900. [PMID:856219] Google Scholar29. Harris MD, Siegel LB, Alloway JA. Gout and hyperuricemia. Am Fam Physician. 1999;59:925-34. [PMID:10068714] Google Scholar30. Wallace SL, Singer JZ. Therapy in gout. Rheum Dis Clin North Am. 1988;14:441-57. [PMID:3051159] Google Scholar31. Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2002:CD002296. [PMID:12519573] Google Scholar32. Terkeltaub RA. Colchicine update: 2008. Semin Arthritis Rheum. 2009;38:411-9. [PMID:18973929] Google Scholar33. Ahern MJ, Reid C, Gordon TP, et al. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med. 1987;17:301-4. [PMID:3314832] Google Scholar34. Baker JF, Schumacher HR. Update on gout and hyperuricemia. Int J Clin Pract. 2009. [PMID:19909378] Google Scholar35. Terkeltaub R, Furst DE, Bennett K, et al. Colchicine efficacy assessed by time to 50% reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the AGREE trial (poster). American College of Rheumatology Annual Scientific Meeting; 19 October 2009; Philadelphia. Accessed at http://acr.confex.com/acr/2009/webprogram/Paper15030.html on 18 December 2009. Google Scholar36. Janssens HJ, Janssen M, van de Lisdonk EH, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008;371:1854-60. [PMID:18514729] Google Scholar37. EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65:1312-24. [PMID:16707532] Google Scholar38. Perez-Ruiz F, Calabozo M, Pijoan JI, et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002;47:356-60. [PMID:12209479] Google Scholar39. Perez-Ruiz F, Atxotegi J, Hernando I, et al. Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study. Arthritis Rheum. 2006;55:786-90. [PMID:17013833] Google Scholar40. Avram Z, Krishnan E. Hyperuricaemia—where nephrology meets rheumatology. Rheumatology (Oxford). 2008;47:960-4. [PMID:18443007] Google Scholar41. Chao J, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep. 2009;11:135-40. [PMID:19296886] Google Scholar42. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76:47-56. [PMID:6691361] Google Scholar43. Braden GL, Warzynski MJ, Golightly M, et al. Cell-mediated immunity in allopurinol-induced hypersensitivity. Clin Immunol Immunopathol. 1994;70:145-51. [PMID:8299230] Google Scholar44. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450-61. [PMID:16339094] Google Scholar45. Schumacher HR Jr, Becker MA, Lloyd E, et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009;48:188-94. [PMID:19141576] Google Scholar46. Edwards NL. Febuxostat: a new treatment for hyperuricaemia in gout. Rheumatology (Oxford). 2009;48 Suppl 2:ii15-ii19. [PMID:19447778] Google Scholar47. Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004;31:2429-32. [PMID:15570646] Google Scholar48. Justiniano M, Dold S, Espinoza LR. Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine. J Clin Rheumatol. 2007;13:266-8. [PMID:17921794] Google Scholar49. So A, De Smedt T, Revaz S, et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9:R28. [PMID:17352828] Google Scholar50. Wolfe F, Cathey MA. The misdiagnosis of gout and hyperuricemia. J Rheumatol. 1991;18:1232-4. [PMID:1941830] Google Scholar51. Roddy E, Mallen CD, Hider SL, et al. Prescription and comorbidity screening following consultation for acute gout in primary care. Rheumatology (Oxford). 2010;49:105-11. [PMID:19920095] Google Scholar52. Barber C, Thompson K, Hanly JG. Impact of a rheumatology consultation service on the diagnostic accuracy and management of gout in hospitalized patients. J Rheumatol. 2009;36:1699-704. [PMID:19567626] Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCorrection: In the Clinic: Gout Metrics Cited byManagement of Hyperosmotic HyperglycemiaCase 29-2017A Primary Care Perspective on GoutHigh Serum Uric Acid Levels Are Associated with All-Cause and Cardiovascular, but Not Cancer, Mortality in Elderly AdultsA biohybrid hydrogel for the urate-responsive release of urate oxidaseCorrection: In the Clinic: Gout 2 February 2010Volume 152, Issue 3Page: ITC2-1KeywordsAllopurinolArthritisColchicineDiureticsDrugsGoutInflammationNSAIDsRheumatologyUric acid ePublished: 2 February 2010 Issue Published: 2 February 2010 Copyright & PermissionsCopyright © 2010 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...